109
Views
17
CrossRef citations to date
0
Altmetric
Research Article

Longitudinal studies of patients with ANCA vasculitis demonstrate concurrent reactivity to complementary PR3 protein segments cPR3m and cPR3C and with no reactivity to cPR3N

, , , &
Pages 98-106 | Received 09 Mar 2010, Accepted 05 May 2010, Published online: 16 Aug 2010

References

  • Shoenfeld Y. The idiotypic network in autoimmunity: Antibodies that bind antibodies that bind antibodies. Nat Med. 2004; 10:17–18.
  • McGuire KL, Holmes DS. Role of complementary proteins in autoimmunity: An old idea re-emerges with new twists. Trends Immunol. 2005; 26:367–372.
  • Pendergraft WFIII, Preston GA, Shah RR, Tropsha A, Carter CWJr., Jennette JC, Falk RJ. Autoimmunity is triggered by cPR-3(105–201), a protein complementary to human autoantigen proteinase-3. Nat Med. 2004; 10:72–79.
  • Heal JR, Roberts GW, Raynes JG, Bhakoo A, Miller AD. Specific interactions between sense and complementary peptides: The basis for the proteomic code. Chembiochem. 2002; 3:136–151.
  • Yang J, Bautz DJ, Lionaki S, Hogan SL, Chin H, Tisch RM, Schmitz JL, Pressler BM, Jennette JC, Falk RJ, Preston GA. ANCA patients have T cells responsive to complementary PR-3 antigen. Kidney Int. 2008; 74:1159–1169.
  • Bautz DJ, Preston GA, Lionaki S, Hewins P, Wolberg AS, Yang JJ, Hogan SL, Chin H, Moll S, Jennette JC, Falk RJ. Antibodies with dual reactivity to plasminogen and complementary PR3 in PR3-ANCA vasculitis. J Am Soc Nephrol. 2008; 19:2421–2429.
  • Selga D, Segelmark M, Wieslander J, Gunnarsson L, Hellmark T. Epitope mapping of anti-PR3 antibodies using chimeric human/mouse PR3 recombinant proteins. Clin Exp Immunol. 2004; 135:164–172.
  • Rarok AA, van der Geld YM, Stegeman CA, Limburg PC, Kallenberg CG. Diversity of PR3-ANCA epitope specificity in Wegener's granulomatosis. Analysis using the biosensor technology. J Clin Immunol. 2003; 23:460–468.
  • Williams RCJr., Staud R, Malone CC, Payabyab J, Byres L, Underwood D. Epitopes on proteinase-3 recognized by antibodies from patients with Wegener's granulomatosis. J Immunol. 1994; 152:4722–4737.
  • Van Der Geld YM, Simpelaar A, Van Der Zee R, Tervaert JW, Stegeman CA, Limburg PC, Kallenberg CG. Antineutrophil cytoplasmic antibodies to proteinase 3 in Wegener's granulomatosis: Epitope analysis using synthetic peptides. Kidney Int. 2001; 59:147–159.
  • Griffith ME, Coulthart A, Pemberton S, George AJ, Pusey CD. Anti-neutrophil cytoplasmic antibodies (ANCA) from patients with systemic vasculitis recognize restricted epitopes of proteinase 3 involving the catalytic site. Clin Exp Immunol. 2001; 123:170–177.
  • Erlanger BF, Cleveland WL, Wassermann NH, Ku HH, Hill BL, Sarangarajan R, Rajagopalan R, Cayanis E, Edelman IS, Penn AS. Auto-anti-idiotype: A basis for autoimmunity and a strategy for anti-receptor antibodies. Immunol Rev. 1986; 94:23–37.
  • Hill BL, Erlanger BF. Monoclonal antibodies to the thyrotropin receptor raised by an autoantiidiotypic protocol and their relationship to monoclonal autoantibodies from Graves' patients. Endocrinology. 1988; 122:2840–2850.
  • Erlanger BF. Auto-anti-idiotypy, autoimmunity and some thoughts on the structure of internal images. Int Rev Immunol. 1989; 5:131–137.
  • Shoenfeld Y. Idiotypic induction of autoimmunity: A new aspect of the idiotypic network. FASEB J. 1994; 8:1296–1301.
  • Munthe LA, Kyte JA, Bogen B. Resting small B cells present endogenous immunoglobulin variable-region determinants to idiotope-specific CD4(+) T cells in vivo. Eur J Immunol. 1999; 29:4043–4052.
  • Munthe LA, Os A, Zangani M, Bogen B. MHC-restricted Ig V region-driven T-B lymphocyte collaboration: B cell receptor ligation facilitates switch to IgG production. J Immunol. 2004; 172:7476–7484.
  • Huelseweh B, Kohl B, Hentschel H, Kinne RK, Werner A. Translated anti-sense product of the Na/phosphate co-transporter (NaPi-II). Biochem J. 1998; 332 Pt 2: 483–489.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.